This article was originally published in Start Up
Receptos isn't the only company in the G-coupled protein receptor oral MS drug arena, but it believes its proprietary S1P1 agonist will improve on Novartis' first-in-class S1P1 modulator Gilenya. Unlike Gilenya, which hits four of the five S1P receptor subtypes, the Receptos molecule binds selectively to S1P1 and has a predicted human half-life of approximately one day, potentially improving the safety profile and reducing complications for MS patients.
You may also be interested in...
Plus news on recent financings by Vivus, Novira Therapeutics, Theraclone Sciences and Receptos.
The $100 million venture fund is the first to use the rights universities hold – but rarely exercise – to make venture bets. So far, with a share of Osage’s profits as incentive, dozens of schools have been happy to share.
Biopharma and medical device start-ups brought in a total of $216 million in Q1 2011. Absent were any financings involving in vitro diagnostics companies. Only four acquisitions involving start-ups were completed - one in biopharma and three in the device industry. Cancer was the most popular therapeutic category among biopharma start-up alliance this quarter.